Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Cellulitis: later-stage trial registry
A small indexed set (12 trials) with no open enrollment listed right now.
Corpus placement: #1,429 of 28,707 conditions by registered trial count.
12 US clinical trials · none currently recruiting · #1,429 of 28,707 conditions by registered trial count
Cellulitis: 12 US clinical trials tracked, none currently recruiting.
Cellulitis is the subject of 12 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 6 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Melinta Therapeutics, running 2 of these trials.
Enrollment posture brief
Registry condition cellulitis
OPEN 0 | RECR 0% | LATE 6 | EARLY 2 | RANK #1429 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Adenocarcinoma of the Gastroesophageal Junction (0% recruiting · 8 trials)
Cellulitis has no open enrollment in this registry pull (12 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Cellulitis on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Cellulitis is recruiting below its size-band peers.
0 of 12 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Cellulitis research.
Melinta Therapeutics accounts for 2 of 12 trials (16.7%). 11 distinct sponsors appear on at least one study for this condition label.
-
Typical Cellulitis enrolment sits around 416 participants.
Median target enrolment is 416 among the 12 trials that report a genuine target (sentinel values excluded). 3 of those (25%) plan for fewer than 100 participants.
-
Cellulitis research is mostly interventional.
11 interventional and 1 observational studies make up this index (91.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Indexed trials (enrollment closed)
12 total, page 1 of 1
Quasi-Randomized Evaluation of the UCLA Next Day Clinic (NDC)
University of California, Los Angeles
NCT06526884
Decreasing Antibiotic Duration for Skin and Soft Tissue Infection Using Behavioral Economics in Primary Care
Nationwide Children's Hospital
NCT05226260
Oritavancin Versus IV Vancomycin for the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infection
Melinta Therapeutics
NCT01252732
Oritavancin Versus IV Vancomycin for the Treatment of Participants With Acute Bacterial Skin and Skin Structure Infection (SOLO I)
Melinta Therapeutics
NCT01252719
Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections
Durata Therapeutics Inc., an affiliate of Allergan
NCT01339091
Utility of Thermal Imaging in Diagnosis of Cellulitis for Lower Extremity Complaints in the Emergency Department
University of Wisconsin, Madison
NCT04928235
Phase 2 Trial of TD 6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI)
Cumberland Pharmaceuticals
NCT00061633
Evaluation of Daptomycin for the Emergency Department Treatment of Complicated Skin and Skin Structure Infections
University of Cincinnati
NCT01549613
Incision and Drainage Versus Needle Aspiration in Soft Tissue Abscesses
University of Massachusetts, Worcester
NCT01085929
Aquacel Versus Iodoform Gauze for Filling Abscess Cavity Following Incision and Drainage
Valleywise Health
NCT00984022
Study Comparing CUBICIN® (Daptomycin for Injection) With Vancomycin in Cellulitis or Erysipelas
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
NCT00295178
Use of a Single Dose of Oral Prednisone in the Treatment of Cellulitis
Albert Einstein Healthcare Network
NCT01671423
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 2 |
| Phase 3 | 4 |
| Phase 4 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Cellulitis records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Cellulitis trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Cellulitis page
12 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- No Cellulitis trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Melinta Therapeutics sponsors the most Cellulitis trials on record, review their full trial history before evaluating a specific study. See Melinta Therapeutics's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Cellulitis condition card totals 12 registered trials; most-linked intervention IV Vancomycin; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.